These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Author: Huang C, Bei L, Liu T.
    Journal: Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693.
    Abstract:
    OBJECTIVE: CA50 and CA242 are newly recognized serum tumor marker. This study is to show their value in the diagnosis of digestive tract tumor. METHODS: 164 patients with malignant digestive disease and 69 patients with benign disease were chosen. CA50 and CA242 level of these patients were measured by immunoradiometric assay. RESULTS: The total sensitivity of CA50 and CA242 are 70% and 63% respectively. Two tumor markers rarely elevated in the patients with benign disease (false positive rate CA50 7.3%, CA242 4.3%). High percentage of elevated CA242 level was recorded in the patients with pancreatic and biliary cancers (Sensitivity 79%). Both have low sensitivity in patients with liver carcinoma. CONCLUSIONS: CA50 and CA242 are valuable marker in the diagnosis of digestive tract tumor.
    [Abstract] [Full Text] [Related] [New Search]